{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:27:15Z","timestamp":1777411635072,"version":"3.51.4"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004476","name":"Chinese Center for Disease Control and Prevention","doi-asserted-by":"publisher","award":["131031001000150001"],"award-info":[{"award-number":["131031001000150001"]}],"id":[{"id":"10.13039\/501100004476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"publisher","award":["grant numbers 2021YFC2301600 and 2022YFC0870200"],"award-info":[{"award-number":["grant numbers 2021YFC2301600 and 2022YFC0870200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emergency Key Program of Guangzhou Laboratory","award":["SRPG22\u2013009"],"award-info":[{"award-number":["SRPG22\u2013009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Using a prospective, observational cohort study during the post\u2013\u201cdynamic COVID-zero\u201d wave in China, we estimated short-term relative effectiveness against Omicron BA.5 infection of inhaled aerosolized adenovirus type 5\u2013vectored ancestral strain coronavirus disease 2019 (COVID-19) vaccine as a second booster dose approximately 1 year after homologous boosted primary series of inactivated COVID-19 vaccine compared with no second booster. Participants reported nucleic acid or antigen test results weekly until they tested positive or completed predesignated follow-up. After excluding participants infected &amp;lt;14 days after study entry, relative effectiveness among the 6576 participants was 61% in 18- to 59-year-olds and 38% in \u226560-year-olds and was sustained for 12 weeks.<\/jats:p>","DOI":"10.1093\/infdis\/jiad338","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:34:24Z","timestamp":1691760864000},"page":"117-121","source":"Crossref","is-referenced-by-count":13,"title":["An Observational Prospective Cohort Study of Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection of an Aerosolized, Inhaled Adenovirus Type 5\u2013Vectored Coronavirus Disease 2019 Vaccine Given as a Second Booster Dose in Guangzhou City, China"],"prefix":"10.1093","volume":"229","author":[{"given":"Fu-Zhen","family":"Wang","sequence":"first","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Huan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program Planning, Guangzhou Center for Disease Control and Prevention , Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance E","family":"Rodewald","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program Planning, Guangzhou Center for Disease Control and Prevention , Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ji","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program Planning, Guangzhou Center for Disease Control and Prevention , Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Fang","family":"Huang","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"},{"name":"Department of Immunization Program, Fujian Provincial Center for Disease Control and Prevention , Fuzhou , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao-Di","family":"Huang","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ming","family":"Bao","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou-Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program Planning, Guangzhou Center for Disease Control and Prevention , Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-5326","authenticated-orcid":false,"given":"Zun-Dong","family":"Yin","sequence":"additional","affiliation":[{"name":"National Immunization Program, Chinese Center for Disease Control and Prevention , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"2024011216402375700_jiad338-B1","author":"World Health Organization","year":"2022"},{"key":"2024011216402375700_jiad338-B2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/22221751.2022.2030199","article-title":"Safety, mucosal and systemic immunopotency of an aerosolized adenovirus vectored vaccine against SARS-CoV-2 in rhesus macaques","volume":"11","author":"Xu","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2024011216402375700_jiad338-B3","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024011216402375700_jiad338-B4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024011216402375700_jiad338-B5","author":"Chinese Center for Disease Control and Prevention","year":"2023"},{"key":"2024011216402375700_jiad338-B6","author":"World Health Organization","year":"2021"},{"key":"2024011216402375700_jiad338-B7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024011216402375700_jiad338-B8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12916-022-02606-8","article-title":"Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death","volume":"20","author":"Huang","year":"2022","journal-title":"BMC Med"},{"key":"2024011216402375700_jiad338-B9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/infdis\/jiad090","article-title":"Real-world effectiveness of primary series and booster doses of inactivated coronavirus disease 2019 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study","volume":"228","author":"Tang","year":"2023","journal-title":"J Infect Dis"},{"key":"2024011216402375700_jiad338-B10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","article-title":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial","volume":"11","author":"Tang","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024011216402375700_jiad338-B11","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2022.2155251","article-title":"Antibody persistence and safety after heterologous boosting with orally aerosolized Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial","volume":"12","author":"Jin","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"2024011216402375700_jiad338-B12","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1016\/j.vaccine.2023.04.013","article-title":"Promises and challenges of mucosal COVID-19 vaccines","volume":"41","author":"Rathore","year":"2023","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad338\/51147215\/jiad338.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/117\/55572210\/jiad338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/117\/55572210\/jiad338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:14:06Z","timestamp":1705083246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/1\/117\/7241332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,11]]},"published-print":{"date-parts":[[2024,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad338","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,15]]},"published":{"date-parts":[[2023,8,11]]}}}